Discontinue Anticoagulation After 3 Months—Do Not Continue for One Year
For a DVT provoked by prolonged sitting (long-hour sitting), you should stop anticoagulation after completing 3 months of therapeutic treatment rather than continuing for one year. If you have already decided to extend beyond 3 months despite guideline recommendations, and the patient has completed at least 6 months of therapeutic anticoagulation, then switch to reduced-dose apixaban 2.5 mg twice daily rather than continuing therapeutic dosing.
Why This DVT Should Not Receive Extended Anticoagulation
The 2021 CHEST guidelines provide clear direction here 1. Prolonged sitting qualifies as a minor transient risk factor for VTE—it is temporary, modifiable, and time-limited. The guidelines explicitly recommend against extended-phase anticoagulation for VTE provoked by minor transient risk factors (weak recommendation, moderate-certainty evidence) 1.
The distinction is critical:
- Major transient risk factors include surgery with general anesthesia >30 minutes or hospitalization with bed confinement for ≥3 days 1
- Minor transient risk factors include situations like prolonged sitting, minor trauma, or short-term immobility
- Your patient's scenario (long-hour sitting) falls into the minor transient category
The standard approach is 3 months of therapeutic anticoagulation, then stop. Extended therapy is reserved for unprovoked VTE or VTE with persistent risk factors 1.
If You've Already Committed to Extended Treatment
If the clinical decision has already been made to continue anticoagulation for one year (perhaps due to patient-specific concerns about recurrence risk or ongoing risk factors you haven't mentioned), then the dosing strategy is clear from both guidelines and FDA labeling:
Switch to Reduced-Dose After 6 Months of Therapeutic Treatment
Use apixaban 2.5 mg twice daily for extended-phase therapy 1, 2. This is the FDA-approved regimen for "reduction in the risk of recurrence of DVT and PE" after completing at least 6 months of treatment 2.
The treatment sequence should be:
- Days 1-7: Apixaban 10 mg twice daily
- Months 1-6: Apixaban 5 mg twice daily
- Month 6 onward (if extending): Apixaban 2.5 mg twice daily
Evidence Supporting Reduced-Dose for Extended Therapy
The 2021 CHEST guidelines suggest using reduced-dose apixaban (2.5 mg twice daily) over full-dose for extended-phase anticoagulation (weak recommendation, very low-certainty evidence) 1. This recommendation balances efficacy against bleeding risk—the reduced dose maintains VTE prevention while minimizing hemorrhagic complications.
A 2025 trial (HI-PRO) demonstrated that low-intensity apixaban 2.5 mg twice daily in patients with provoked VTE and enduring risk factors reduced symptomatic recurrent VTE from 10.0% to 1.3% compared to placebo (HR 0.13,95% CI 0.04-0.36, P<0.001) with only 1 major bleeding event in the apixaban group 3. This supports the efficacy and safety of the reduced dose even in selected provoked VTE patients with additional risk factors.
Critical Pitfalls to Avoid
Do not continue therapeutic-dose apixaban (5 mg twice daily) for extended prophylaxis. The FDA label and guidelines are explicit: after completing initial treatment (minimum 6 months), the dose for extended therapy is 2.5 mg twice daily 2. Continuing full therapeutic dosing unnecessarily increases bleeding risk without additional VTE prevention benefit.
Reassess the decision annually. Even if extended anticoagulation is initiated, the 2021 CHEST guidelines emphasize that this decision should be reevaluated at least annually and with any significant change in health status 1. The risk-benefit balance may shift over time, particularly as the transient provoking factor becomes more remote.
Consider whether anticoagulation is truly indicated beyond 3 months. Unless there are persistent risk factors you haven't described (active cancer, thrombophilia with positive family history, antiphospholipid syndrome), the evidence does not support extending anticoagulation for a provoked DVT from prolonged sitting 1.